Kevin Kelly Named President of BD Surgery Business

WARWICK, R.I. (July 17, 2020) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Kevin Kelly to worldwide president, BD Surgery, effective October 1.

In his new role, Kevin will have responsibility for driving global strategic, operational and commercial performance across the Surgery business portfolio, maintaining a cadence of continuous innovation while further enhancing the customer experience.

“Kevin is an established leader in the medical technology industry who is well acquainted with our Surgery portfolio from his time leading Corporate Healthcare Services at C. R. Bard,” said Simon Campion, president of BD’s Interventional Segment. “Kevin’s track record of leading and developing high-performing teams across our organization makes him uniquely qualified to continue growing our Surgery business in close alignment with the overall BD strategy.”

Kevin has more than 20 years of executive leadership experience in the medical technology industry, including the past decade within the Bard and BD organizations. He joined Bard Electrophysiology (BEP) in 2010 as vice president of sales and subsequently took on the added responsibility of leading BEP marketing. In 2011, he was promoted to vice president and general manager, BEP. Following the division’s divestiture in 2013, Kevin was promoted to president of Corporate Healthcare Services for C. R. Bard, where he led key account and national account activities. Following the acquisition of Bard by BD, he joined the organization’s U.S. Region as vice president and general manager of Medication Delivery Solutions in 2018.


# # #

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit



Troy Kirkpatrick        
BD Public Relations   

Monique N. Dolecki
BD Investor Relations